PFM Health Sciences’s Neurocrine Biosciences NBIX Stock Holding History

PFM Health Sciences’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$36M	Sell	213,407 -2,271	-1%	-$337K	3.09%	7
2026 Q1	$28.4M	Buy	215,678 +52,481	+32%	+$6.96M	2.59%	9
2025 Q4	$23.1M	Buy	163,197 +105,951	+185%	+$15.3M	2.31%	10
2025 Q3	$8.04M	Buy	57,246 +44,425	+347%	+$6.02M	0.62%	44
2025 Q2	$1.61M	Buy	+12,821	New	+$1.47M	0.14%	52
2025 Q1	–	Sell	-166,803	Closed	-$22.8M	–	83
2024 Q4	$22.8M	Buy	+166,803	New	+$20.6M	1.41%	22
2022 Q1	–	Sell	-394,058	Closed	-$33.6M	–	73
2021 Q4	$33.6M	Sell	394,058 -470,021	-54%	-$43.2M	1.14%	40
2021 Q3	$82.9M	Sell	864,079 -251,925	-23%	-$23.8M	2.44%	13
2021 Q2	$109M	Buy	1,116,004 +60,494	+6%	+$5.8M	3.4%	5
2021 Q1	$103M	Buy	+1,055,510	New	+$111M	3.13%	5

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

PFM Health Sciences's NBIX Position: Q2 2026 in Review

PFM Health Sciences reduced its Neurocrine Biosciences (NBIX) stake by 1.1% in Q2 2026, selling an estimated $337K and leaving 213,407 shares worth $36M. The position accounts for 3.09% of the portfolio, ranked #7.

PFM Health Sciences first reported a position in NBIX in Q1 2021 and has held it in 10 quarters since. The position peaked at $109M in Q2 2021. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

PFM Health Sciences held 213,407 shares of Neurocrine Biosciences worth $36M as of Q2 2026.
PFM Health Sciences sold 2,271 Neurocrine Biosciences shares in Q2 2026, an estimated $337K.
Neurocrine Biosciences made up 3.09% of PFM Health Sciences's portfolio in Q2 2026, its #7 holding.
PFM Health Sciences first reported a position in Neurocrine Biosciences in Q1 2021 and has held it in 10 quarters since.
PFM Health Sciences's Neurocrine Biosciences position peaked at $109M in Q2 2021.
777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on PFM Health Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.